* Clink on the link to download
- Adulterated Herbal products on the market
- Certification of premises used to supply restricted drugs within institutions conducting clinical trials
- CIRCULAR NO 031
- Circular no. 032- Presence of a potentially genotoxic impurity, N-nitrosodimethylamine (NDMA) in Ranitidine
- Circular no.2 – suspension of registration of products from the drug register
- Circular no.23 -suspension of registration of products from the Drug register
- Clarification on Hydrochlorothiazide
- Communication circular on Clinical Trial new format for CT certificates
- Detection of Impurity in the Active Pharmaceutical Ingredient (API) valsartan manufactured by Zhejiang Huahai Pharmaceuticals, Linhai, China
- Disabling and potentially permanent side effects associated with quinolone and fluoroquinolone antibiotics
- Furosemide injection manufactured by Grand pharmaceutical (china) co., ltd; batch number 180120
- Guidance on legal requirements for importation of drugs into Uganda
- Implementation of Good Distribution Practices (GDP)
- Increased risk of non-melanoma skin cancer associated with HCTZ
- Institutional Pharmacies amended
- Licensing of Drug shops for 2019
- Licensing of pharmacies in private hospitals and medical centers
- Licensing of pharmacies in private hospitals and medical centers
- New registration numbers (NDAMIS numbers) for Herbal medicines
- New registration numbers (NDAMIS numbers) for Veterinary Drugs
- Prescription records
- Re-registration of pharmaceutical products
- Records of prescriptions
- Records of wholesale pharmacies
- Regulation of chemicals scheduled under the third schedule (Group II) of the National Drug Policy and Authority Act (Cap 2016)
- Response to suggested amendments to the Guidelines on submitting periodic safety update report and any other reports that may be relevant to determine the safety, efficacy and quality of a drug
- Retention of products for financial year 2018 / 2019
- Risk of crystalization of Mannitol 20% iv solution
